Rayo®-Tabs Lactose Tablets

£11.00£880.00 or from £10.45£836.00 / month

Select options This product has multiple variants. The options may be chosen on the product page
Shopping Cart

No products in the cart.

Rayo®-Tabs Lactose Tablets

£11.00£880.00 or from £10.45£836.00 / month

Rayo®-Tabs Lactose Tablets

Monthly subscription available.

SKU: N/A Categories: ,

Rayo®-Tabs Lactose Tablets

Rayo®-Tabs are lentil-shaped lactose tablets that can be energised as frequency carriers. They can be energised with either a Rayocomp PS 1000 polar 4.0 or a Rayocomp PS 10.

Rayo®-Tabs are placed in the Measuring Cup connected to the bioresonance device and the desired frequencies are then transferred to the lactose tablets. It is also possible to duplicate the energetic properties of substances. This involves transferring the frequencies of the substance to the Rayo®-Tabs.

Rayo®-Tabs are therefore ideal for studying the energetic properties of substances or for testing placebo effects. In this case, the test subject takes three Rayo®-Tabs three times a day. As a trial typically lasts 14 days, the small doses contain 126 lactose tablets (3 x 3 x 14).

Note: We would like to take this opportunity to point out that the manufacture and sale of substances that are said to have a healing effect is reserved exclusively for authorised specialists. It is forbidden to manufacture Rayo®-Tabs as a medicinal product and to make statements about any possible healing properties.

Ingredients: 99.25 % lactose, 0.75 % magnesium stearate

Weight 0.033 kg
Dimensions N/A

1000, 1000 x 10, 126, 126 x 10, 126 x 100


There are no reviews yet.

Be the first to review “Rayo®-Tabs Lactose Tablets”

Your email address will not be published. Required fields are marked *


Please note that the information, advice and solutions provided by Rayonex originate from over 40 years of experience in the Biomedical field.

Furthermore, it is indicated that traditional orthodox medicinal practices do not accept or even recognise the effects of bioenergetic oscillations, even with existing clinical prospective, double-blind randomised, and placebo controlled studies.